Kronik Miyeloid Lösemili Hastaların CD34+ Hücrelerinde Gen İfade Profili
Abstract
Objectives: Chronic myeloid leukaemia (CML) is a malignant, clonal and proliferative disease originating from haematopoietic stem cells. The aim of this study is to use bioinformatic analysis to identify potential key genes and pathways involved in CML patients in the chronic phase to investigate the molecular mechanisms of CML.
Materials and Methods: For bioinformatic analysis, mRNA microarray data of CD34+ cells from 9 CML patients and 8 healthy individuals with accession number GSE5550 were downloaded from the Gene Expression Omnibus (GEO) database. Samples from CML patients and healthy individuals were analysed with GEO2R to find differentially expressed genes (DEGs). Gene ontology and Kyoto gene and genome encyclopedia enrichment analyses and protein-protein interaction network analysis were performed for DEGs and important CML related genes were identified.
Results: After analysis with GEO2R, DEGs with p<0.01 and log2FC<0, log2FC>0 were selected. In the GSE5550 data set, the expression of 1894 genes increased and 796 genes decreased in CML patients compared to the healthy control group. It was observed that DEGs were enriched in pathways such as metabolic pathways, RNA transport, ribosome, protein processing in endoplasmic reticulum and Ubikitin-mediated proteolysis in the CML patient group in comparison to the healthy controls. In addition, RPL35, RPL39, RPS12, eEF1A1, RPLP1, RPL12, ODC1, PSMD7, USP14, PSMA1, GLI2, PSMC6 were identified as the most important candidate genes.
Conclusion: The results of our study showed that the genes and pathways identified in our study may be biomarker candidates that can be used in
drug treatment to target leukaemic stem cells.
Keywords
CML, bioinformatic analysis, microarray, gene expression
Ethical Statement
Etik kurul onayı tüm veriler anonim olduğundan bu çalışma için geçerli ve gerekli değildir.
References
- 1. Cokic VP, Mojsilovic S, Jaukovic A, et al. Gene expression profile of circulating CD34(+) cells and granulocytes in chronic myeloid leukemia. Blood Cells Mol Dis. 2015;55:373-381.
- 2. Diaz-Blanco E, Bruns I, Neumann F, et al. Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia. 2007;21:494-504.
- 3. Soverini S, De Santis S, Monaldi C, et al. Targeting Leukemic Stem Cells in Chronic Myeloid Leukemia: Is It Worth the Effort? Int J Mol Sci.2021;22:7093.
- 4. FApperley J. Part II: Management of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncology. 2007;8:1116-1128.
- 5. Keramatinia A, Ahadi A, Akbari ME, et al. Genomic Profiling of Chronic Myelogenous Leukemia: Basic and Clinical Approach. Journal of Cancer Prevention. 2017;22:74-81.
- 6. O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New England Journal of Medicine. 2003;348:994-1004.
- 7. Chomel JC, Bonnet ML, Sorel N, et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood. 2011;118:3657-3660.
- 8. Chu S, McDonald T, Lin A, et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood. 2011;118:5565-5572.
- 9. Holyoake T, Jiang XY, Eaves C, et al. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia.Blood. 1999;94:2056-2064.
- 10. Gao CD, Zhou C, Zhuang J, et al. Identification of key candidate genes and miRNA-mRNA target pairs in chronic lymphocytic leukemia by integrated bioinformatics analysis. Molecular Medicine Reports. 2019;19:362-374.